On Friday, NewAmsterdam Pharma Company NV (NASDAQ: NAMS) opened lower -3.90% from the last session, before settling in for the closing price of $21.03. Price fluctuations for NAMS have ranged from $14.06 to $27.29 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 30.12% at the time writing. With a float of $62.21 million, this company’s outstanding shares have now reached $112.17 million.
Let’s look at the performance matrix of the company that is accounted for 68 employees. In terms of profitability, gross margin is 100.0%, operating margin of -402.49%, and the pretax margin is -397.45%.
NewAmsterdam Pharma Company NV (NAMS) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of NewAmsterdam Pharma Company NV is 44.59%, while institutional ownership is 57.42%. The most recent insider transaction that took place on May 15 ’25, was worth 5,598,975. Before that another transaction happened on Apr 11 ’25, when Company’s Affiliate proposed sale 1,433,193 for $15.12, making the entire transaction worth $21,669,878.
NewAmsterdam Pharma Company NV (NAMS) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 30.12% per share during the next fiscal year.
NewAmsterdam Pharma Company NV (NASDAQ: NAMS) Trading Performance Indicators
Check out the current performance indicators for NewAmsterdam Pharma Company NV (NAMS). In the past quarter, the stock posted a quick ratio of 19.98. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 48.13.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.88, a number that is poised to hit -0.49 in the next quarter and is forecasted to reach -2.07 in one year’s time.
Technical Analysis of NewAmsterdam Pharma Company NV (NAMS)
NewAmsterdam Pharma Company NV (NASDAQ: NAMS) saw its 5-day average volume 1.08 million, a positive change from its year-to-date volume of 0.87 million. As of the previous 9 days, the stock’s Stochastic %D was 61.03%. Additionally, its Average True Range was 1.32.
During the past 100 days, NewAmsterdam Pharma Company NV’s (NAMS) raw stochastic average was set at 58.85%, which indicates a significant decrease from 62.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 57.19% in the past 14 days, which was lower than the 59.07% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $18.20, while its 200-day Moving Average is $20.13. Nevertheless, the first resistance level for the watch stands at $21.41 in the near term. At $22.62, the stock is likely to face the second major resistance level. The third major resistance level sits at $23.32. If the price goes on to break the first support level at $19.50, it is likely to go to the next support level at $18.80. Assuming the price breaks the second support level, the third support level stands at $17.59.
NewAmsterdam Pharma Company NV (NASDAQ: NAMS) Key Stats
There are currently 112,271K shares outstanding in the company with a market cap of 2.27 billion. Presently, the company’s annual sales total 45,560 K according to its annual income of -241,600 K. Last quarter, the company’s sales amounted to 2,980 K and its income totaled -39,530 K.
